F1000Research (Oct 2022)

Integration of single-cell RNA sequencing and spatial transcriptomics to reveal the glioblastoma heterogeneity [version 1; peer review: 2 approved, 1 approved with reservations]

  • Bozena Kaminska,
  • Urszula Lawrynowicz,
  • Monika Horbacz,
  • Jakub Mieczkowski,
  • Adrian Perdyan

Journal volume & issue
Vol. 11

Abstract

Read online

Glioblastoma (GBM), a deadly brain tumor, is still one of the few lasting challenges of contemporary oncology. Current therapies fail to significantly improve patient survival due to GBM’s tremendous genetic, transcriptomic, immunological, and sex-dependent heterogeneity. Over the years, clinical differences between males and females were characterized. For instance, higher incidence of GBM in males or distinct responses to cancer chemotherapy and immunotherapy between males and females have been noted. However, despite the introduction of single-cell RNA sequencing and spatial transcriptomics, these differences were not further investigated as studies were focused only on exposing the general picture of GBM heterogeneity. Hence, in this study, we summarized the current state of knowledge on GBM heterogeneity exposed by single-cell RNA sequencing and spatial transcriptomics with regard to genetics, immunology, and sex-dependent differences. Additionally, we highlighted future research directions which would fill the gap of knowledge on the impact of patient’s sex on the disease outcome.

Keywords